Earlier Detection.Zero Gaps.One OrchestratedJourney.End-to-end AI for oncology care, from risk to recovery.
Qure.ai turns routine imaging and clinical data into an AI-enabled intelligence layer across the oncology journey detecting at risk patients earlier, tracking them through every handoff, and driving the guideline concordant actions that shift stage at diagnosis.
Meet the Qure team at ESMO Congress 2026 | Booth #8097
Visit us at Booth #8097
AI-derived imaging biomarkers from chest radiographs, CT scans, radiology reports, and EMR data surface early signs of cancer risk-flagging high-risk and therapy-relevant patients before symptoms do. Early diagnosis, stage-shift opportunity, and scalable patient identification, built into routine care.
By unifying imaging, clinical, and real-time EMR data, Qure.ai's multimodal clinical intelligence layer tracks every flagged patient through referral, work-up, and follow-up-generating real-world evidence along the way and closing the loop that today runs on spreadsheets and phone calls.
Agentic AI powers MDT-based care coordination and guideline-concordant decision support from diagnosis to treatment-reducing patient leakage, shortening time to treatment initiation, and keeping longitudinal tracking in place after the first intervention.
From Signal to Action: Across the Full Care Journey
Book a Meeting
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
